IGF-1 LR3 (Insulin-Like Growth Factor-1, Long R3)
Long-acting insulin-like growth factor-1 (IGF-1) analogue (investigational) · Pre-filled pen
IGF-1 LR3 is a structurally modified, long-acting analogue of IGF-1 that engages the IGF-1 receptor (IGF-1R) and downstream anabolic cascades such as PI3K/AKT/mTOR and MAPK. Its modified structure lowers binding to IGF-binding proteins, which is intended to prolong activity relative to native IGF-1. Evidence for muscle or performance use is very limited and comes mainly from preclinical work.
Studied use areas
- Research into anabolic and protein-synthesis signalling
- Muscle repair and recovery research after training-induced microdamage
- Cell growth, differentiation and tissue-adaptation research
- Body-composition research alongside GH-axis pathways
Safety & status
- Educational information only — not medical advice; use requires physician supervision
- Investigational and not approved for muscle-building or performance; evidence is largely preclinical
- Potent growth-factor signalling can affect blood glucose (hypoglycaemia risk) and involves proliferative pathways that need clinical oversight
- Screening, suitability and any monitoring are determined by the treating physician
⚕ Clinical note: This card is educational and is not medical advice, a protocol or a promise of results. IGF-1 LR3 is investigational; any use must be individualised and supervised by a qualified physician.
Evidence: Investigational (Grade D) — very limited human data, mainly preclinical · References: peer-reviewed IGF-1 and growth-factor physiology literature; preclinical anabolic-signalling studies; EMA/MHRA product and safety information
